Authors : Callejo M; Department of Pharmacology and Toxicology, Facultad de Medicina, School of Medicine, Universidad Complutense de Madrid, Pza Ramón y Cajal s/n., 28040, Madrid, Spain.; CIBER Enfermedades Respiratorias (CibeRes), Madrid, Spain.

Subjects: Receptors, Calcitriol*/Receptors, Calcitriol*/Receptors, Calcitriol*/metabolism ; Receptors, Calcitriol*/Receptors, Calcitriol*/Receptors, Calcitriol*/genetics ; Cell Proliferation*/Cell Proliferation*/Cell Proliferation*/drug effects

Source: Scientific reports [Sci Rep] 2024 Nov 10; Vol. 14 (1), pp. 27445. Date of Electronic Publication: 2024 Nov 10.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

CXCL12/CXCR4 pathway as a novel therapeutic target for RNF213-associated pulmonary arterial hypertension.

Authors : Hiraide T; Department of Cardiology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo, 160-8582, Japan.; Tsuda N

Subjects: Receptors, CXCR4*/Receptors, CXCR4*/Receptors, CXCR4*/metabolism ; Receptors, CXCR4*/Receptors, CXCR4*/Receptors, CXCR4*/genetics ; Ubiquitin-Protein Ligases*/Ubiquitin-Protein Ligases*/Ubiquitin-Protein Ligases*/genetics

Source: Scientific reports [Sci Rep] 2024 Nov 04; Vol. 14 (1), pp. 26604. Date of Electronic Publication: 2024 Nov 04.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment.

Authors : Soh MS; Department of Cardiology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon, 16499, Republic of Korea.; Won KH

Subjects: Amlodipine*/Amlodipine*/Amlodipine*/administration & dosage ; Amlodipine*/Amlodipine*/Amlodipine*/adverse effects ; Amlodipine*/Amlodipine*/Amlodipine*/therapeutic use

Source: Scientific reports [Sci Rep] 2024 Oct 03; Vol. 14 (1), pp. 22940. Date of Electronic Publication: 2024 Oct 03.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Animal models of pulmonary arterial hypertension associated with atrial septal defect.

Authors : Wang L; Department of Pediatrics, Guizhou Children's Hospital, Affiliated Hospital of Zunyi Medical University, 149 Dalian Street, Zunyi, 563000, Guizhou, People's Republic of China.; Tang T

Subjects: Disease Models, Animal* ; Heart Septal Defects, Atrial*/Heart Septal Defects, Atrial*/Heart Septal Defects, Atrial*/complications ; Heart Septal Defects, Atrial*/Heart Septal Defects, Atrial*/Heart Septal Defects, Atrial*/pathology

Source: Scientific reports [Sci Rep] 2024 Aug 07; Vol. 14 (1), pp. 18287. Date of Electronic Publication: 2024 Aug 07.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Autophagy and ubiquitin-dependent proteolysis processes in left ventricular mass loss in pulmonary arterial hypertension.

Authors : Hołda MK; HEART - Heart Embryology and Anatomy Research Team, Department of Anatomy, Jagiellonian University Medical College, Kopernika 12, 31-034, Kraków, Poland. .; Division of Cardiovascular Sciences, The University of Manchester, Manchester, UK. .

Subjects: Autophagy* ; Ubiquitin*/Ubiquitin*/Ubiquitin*/metabolism ; Heart Ventricles*/Heart Ventricles*/Heart Ventricles*/metabolism

Source: Scientific reports [Sci Rep] 2024 Jul 02; Vol. 14 (1), pp. 15133. Date of Electronic Publication: 2024 Jul 02.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors.

Authors : Nakano Y; Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.; Department of Cardiology, Nagoya University Hospital, 65 Tsurumai-cho, Shouwa-ku, Nagoya, 466-8560, Japan.

Subjects: Factor Xa Inhibitors*/Factor Xa Inhibitors*/Factor Xa Inhibitors*/therapeutic use ; Hypertension, Pulmonary*/Hypertension, Pulmonary*/Hypertension, Pulmonary*/drug therapy ; Hypertension, Pulmonary*/Hypertension, Pulmonary*/Hypertension, Pulmonary*/etiology

Source: Scientific reports [Sci Rep] 2024 Oct 28; Vol. 14 (1), pp. 25762. Date of Electronic Publication: 2024 Oct 28.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Exploring the Endothelin-1 pathway in chronic thromboembolic pulmonary hypertension microvasculopathy.

Authors : Feriel B; UMR_S 999 'Pulmonary Hypertension: Pathophysiology and Novel Therapies' (HPPIT), INSERM, Hôpital Marie Lannelongue Et Hôpital Bicêtre, Le Plessis-Robinson Et Le Kremlin-Bicêtre, France.; School of Medicine, University of Paris-Saclay, HPPIT, Le Kremlin-Bicêtre, France.

Subjects: Endothelin-1*/Endothelin-1*/Endothelin-1*/metabolism ; Endothelin-1*/Endothelin-1*/Endothelin-1*/blood ; Hypertension, Pulmonary*/Hypertension, Pulmonary*/Hypertension, Pulmonary*/metabolism

Source: Scientific reports [Sci Rep] 2024 Nov 16; Vol. 14 (1), pp. 28308. Date of Electronic Publication: 2024 Nov 16.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Re-evaluating cardiovascular risk in systolic-dominant, diastolic-dominant and parallelly-elevated hypertension: insights from northeast rural cardiovascular health study.

Authors : Li Q; Department of Cardiology, The First Hospital of China Medical University, 155 Nanjing North Street, Heping District, 110001, Shenyang, Liaoning Province, People's Republic of China.; Wang P

Subjects: Hypertension*/Hypertension*/Hypertension*/epidemiology ; Hypertension*/Hypertension*/Hypertension*/physiopathology ; Hypertension*/Hypertension*/Hypertension*/complications

Source: Scientific reports [Sci Rep] 2024 Nov 10; Vol. 14 (1), pp. 27443. Date of Electronic Publication: 2024 Nov 10.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Deciphering the inhibitory effects of trimetazidine on pulmonary hypertension development via decreasing fatty acid oxidation and promoting glucose oxidation.

Authors : Yanagisawa A; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.; Kim JD

Subjects: Trimetazidine*/Trimetazidine*/Trimetazidine*/pharmacology ; Hypertension, Pulmonary*/Hypertension, Pulmonary*/Hypertension, Pulmonary*/drug therapy ; Hypertension, Pulmonary*/Hypertension, Pulmonary*/Hypertension, Pulmonary*/metabolism

Source: Scientific reports [Sci Rep] 2024 Nov 07; Vol. 14 (1), pp. 27069. Date of Electronic Publication: 2024 Nov 07.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Triglyceride glucose-body mass index as a mediator of hypertension risk in obstructive sleep apnoea syndrome: a mediation analysis study.

Authors : Wang L; General Practice Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Jianghan District, Wuhan, China.; Zou J

Subjects: Sleep Apnea, Obstructive*/Sleep Apnea, Obstructive*/Sleep Apnea, Obstructive*/blood ; Sleep Apnea, Obstructive*/Sleep Apnea, Obstructive*/Sleep Apnea, Obstructive*/complications ; Hypertension*/Hypertension*/Hypertension*/blood

Source: Scientific reports [Sci Rep] 2024 Oct 29; Vol. 14 (1), pp. 25910. Date of Electronic Publication: 2024 Oct 29.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Vitamin D receptor and its antiproliferative effect in human pulmonary arterial hypertension.

CXCL12/CXCR4 pathway as a novel therapeutic target for RNF213-associated pulmonary arterial hypertension.

Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment.

Animal models of pulmonary arterial hypertension associated with atrial septal defect.

Autophagy and ubiquitin-dependent proteolysis processes in left ventricular mass loss in pulmonary arterial hypertension.

Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors.

Exploring the Endothelin-1 pathway in chronic thromboembolic pulmonary hypertension microvasculopathy.

Re-evaluating cardiovascular risk in systolic-dominant, diastolic-dominant and parallelly-elevated hypertension: insights from northeast rural cardiovascular health study.

Deciphering the inhibitory effects of trimetazidine on pulmonary hypertension development via decreasing fatty acid oxidation and promoting glucose oxidation.

Triglyceride glucose-body mass index as a mediator of hypertension risk in obstructive sleep apnoea syndrome: a mediation analysis study.

اتصل بنا

اتبع